Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes

一种红细胞、化合物的技术，应用在药物的器械、其他医疗器械、微型胶囊等方向，能够解决犯错、耗时操作人员、设备不能适当地实施等问题

Active Publication Date: 2013-03-20
ARIDLER CO LTD
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the processing (loading) of red blood cells is relatively time-consuming and involves the risk of operator error
[0016] Known devices cannot properly implement
Due to the fact that they cannot be performed, the procedure needs to be performed in a dedicated structure and it is not possible to operate at a site where patients are more likely to be affected
Furthermore, known devices require continuous intervention by dedicated staff and are not always precise and / or sufficiently effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes
  • Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes
  • Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0161] This example discloses figure 1 operation test of the equipment. The method used hereinafter follows the indications of the operating instructions of the above-mentioned device 1 with respect to the first aspect of the invention.

[0162] Eight experiments loaded with dexamethasone sodium phosphate (500 mg per procedure) were performed in human red blood cells from 50 ml of whole blood from healthy blood donors.

[0163] The materials used for the tests were:

[0164] - Figure 4 s installation;

[0165] - Figure 9 s installation;

[0166] - hypotonic solution 1 (400ml, osmolality 180mOsm / Kg), hypotonic solution 2 (200ml, osmolality 120mOsm / Kg);

[0167] - Resealing hypertonic solution (PIGPA) (about 33mM NaH 2 PO 4 about 1.606M KCl; about 0.194M NaCl; about 0.1M inosine; about 5mM adenine; about 20mM ATP; about 0.1M glucose; about 0.1M pyruvate; and about 4mM MgCl 2 ) (7ml, 2500-3800mOsm / Kg).

[0168] - Dexamethasone sodium phosphate aqueous solution, 500mg / ...

Embodiment 2

[0178] superparamagnetic nanoparticles

[0179] Superparamagnetic nanoparticles are already available and used as contrast agents for magnetic resonance imaging (MRI). However, once infused into the bloodstream by intravenous injection, the nanoparticles are rapidly coated by the plasma components of the blood, a process called opsonization that establishes the vulnerability of the nanoparticles themselves to the body's main defense system, the mononuclear phagocyte system. Identify the key to the assurance. Thus, the encapsulation of superparamagnetic nanoparticles in human erythrocytes has been achieved by the device of the present invention to avoid their rapid clearance from the blood circulation and thus obtain a wider imaging time range in intravascular magnetic resonance applications ( PCT / EP07 / 06349, Delivery of contrasting agents for magnetic resonance imaging). For example, having passed the procedure disclosed above and as an object of the present invention such...

Embodiment 3

[0182] Contrast agent Indocyanine Green (ICG)

[0183] Another application of the innovative technology involving the delivery of exogenous molecules into red blood cells is represented by the encapsulation of contrast agents to be used in fluorescein angiography or other optical and / or fluorescent detection methods. For example, using figure 2 The device shown represents the results obtained for the encapsulation of the contrast agent indocyanine green (ICG). This is proposed as a new strategy for visualization and / or photocoagulation of choroidal neovascularization in retinal degeneration and vascular disease for diagnostic and therapeutic purposes.

[0184] ICG is an FDA-approved tricarbocyanine-containing infrared (IR) contrast agent for diagnostic use in visualizing retinal vascularity and for photodynamic therapy. Its use as a contrast agent takes advantage of the fact that most biomolecules neither absorb nor emit light in the near-infrared region, resulting in int...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A portable and highly automated apparatus and method for introducing at least one compound within erythrocytes is provided. The apparatus (1) comprises a reusable part (56) provided with mechanical elements such as pumps (31, 40, 49) and valves (10, 26, 29, 30, 33, 46, 50) and electronic units such as a control unit (15). The apparatus (1) also comprises a disposable part (55), which is adapted to come into contact with the sample containing the erythrocytes and is provided with a system (2) of tubes made of deformable material, a plurality of reservoirs (6, 13, 21, 27, 28, 39, 48) and one or more filters (37). The apparatus (2) allows a further concentration of the erythrocytes after they have been treated. The apparatus (1) allows to introduce the compound in the erythrocytes in a virtually totally automated manner.

Description

technical field [0001] The present invention relates to devices, kits, uses and methods for introducing at least one compound into red blood cells. Background technique [0002] Recently, many attempts have focused on developing procedures for targeted release of agents at specific sites in the patient's body or to achieve sustained release of drugs in the patient's body. It is known that the effectiveness of a drug can be increased when the drug effectively reaches the appropriate target or when the drug is released preferentially in the organ to be treated or within the cells to be treated. In addition, the toxicity of drugs can be reduced when the total amount of drug administered is minimized but its therapeutic effect is maintained due to the slow release of the drug. Concerns about drug delivery systems range from conventional formulations of mostly relatively simple organic molecules to more complex pharmaceutically active agents such as peptides, proteins, enzymes, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/50A61M1/36A61M1/16
CPCA61M1/3687A61M1/14A61M1/3693A61K9/5068A61M1/16A61M1/3633A61M2202/0429A61M1/3692
Inventor 乔瓦尼·曼布里尼索尼娅·塞拉菲尼
Owner ARIDLER CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com